K's data from KN-024 had PDL1 tumor expression >50% vs BMY's trial which was >5%....could be an issue of trial design here. Link to MRK Note About CheckMate -026 CheckMate -026 is a Phase 3, open-label, randomized study of Opdivo as monotherapy versus investigator's choice chemotherapy in patients with

pp chttp://www.ingdirect.com/mobile?u=m_source=em&utm_medium=cust&utm_campaign=07172012EOXS&utm_term= EM8=607172012EOXS> or =rom your computer with CheckMate remote deposit service =20 • Access to over 35,000 Free ATMs - find a few near you <http://www.ingdirect.com=atm?utm_source=em&utm_medium=cust&utm